Trial · NCT00343460
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of Patients With Complete Response (CR) During Acute Phase (0-24 Hours) After Administration of Chemotherapy Course 1 | 0-24 Hours | Complete Response is defined as no emetic episodes and no use of rescue medications |
| Primary | Proportion of Patients With CR During Delayed-onset Phase (24-120 Hours) After Administration of Chemotherapy Course 1 | 24-120 Hours | Complete Response is defined as no emetic episodes and no use of rescue medications |
| Secondary | Proportion of Patients With Complete Control During the Acute Phase (0-24 Hours), Delayed-onset Phase (24-120 Hours), and During Chemotherapy Course 1 | 0-120 Hours | Complete control is defined as complete response with no more than mild nausea. |
| Secondary | Proportion of Patients With Total Response During the Acute Phase, Delayed-onset Phase, and During Chemotherapy Course 1 | 0-120 Hours | TR during acute phase is defined as Complete Response with no nausea during 0 to 24 hours following the administration of chemotherapy in Cycle 1. TR during delayed-onset phase is defined as Complete Response with no nausea during \>24 to 120 hours following the administration of chemotherapy in Cycle 1. TR during overall risk period is defined as Complete Response with no nausea during 0 to 120 hours following the administration of chemotherapy in Cycle 1. |
| Secondary | Number of Emetic Episodes | Days 1-5 | Number of Emetic Episodes - days 1-5 |
| Secondary | Time to First Treatment Failure | 0-120 Hours | Proportions of subjects event free at 24, 48, 72, 96, and 120 hours after chemotherapy administration |
| Secondary | First and Overall Use of Rescue Medication | 0-120 Hours | |
| Secondary | Severity of Nausea Daily and During Chemotherapy Course 1 (0-120 Hours) | 0-120 Hours | Maximum severity of nausea, days 1-5 |
| Secondary | Sustainability of Antiemetic Effect of APF530 Over Multiple Chemotherapy Courses | 0-120 Hours | Sustainability of Overall Complete Response (CR 0-120 hrs) Over Two, Three, and Four Cycles Complete Response is defined as no emetic episodes and no use of rescue medications |
| Secondary | Quality of Life and the Impact of Nausea and Vomiting on Day 5 | 5 days | Functional Living Index |
| Secondary | Patient's Global Satisfaction With Antiemetic Therapy During Acute Phase and Chemotherapy Course 1 | 0- 24 Hours | Subject who were very satisfied on Day 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00343460/registered